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A new category of phosphonium based cationic amphiphilic peptides has been developed and evaluated
as potential antimicrobial peptides and cell penetrating peptides. The required building blocks were conve-
niently accessible from cysteine and could be applied in a solid phase peptide synthesis protocol for incor-
poration into peptide sequences. Evaluation of the antimicrobial properties and cellular toxicity of these
phosphonium based peptides showed that these “soft” cationic side-chain containing peptides have poor
antimicrobial properties and most of them were virtually non toxic (on HEK cells tested at 256 and 512 μM)
and non-haemolytic (on horse erythrocytes tested at 512 μM), hinting at an interesting potential application
as cell penetrating peptides. This possibility was evaluated using fluorescent peptide derivatives and showed
that these phosphonium based peptide derivatives were capable of entering HEK cells and depending on
the sequence confined to specific cellular areas.
Introduction
Cationic amphiphilic peptides (CAPs) are a class of com-
pounds that are attracting extensive attention in medicinal
chemistry because of their wide range of biological activities.
The broad spectrum antimicrobial properties of antimicrobial
peptides (AMPs)1 are of great interest for the development of
potential new antibiotics, since as compared to the widely
used small molecule antibiotics, virtually no resistance has
been observed so far.2 Also, the membrane permeation capa-
bilities of cell penetrating peptides (CPPs)3 and their low tox-
icity or side effects, will become increasingly important for
the intra-cellular delivery of small molecule drugs and
biologics.4–6
All these activities are a consequence of the amphipathic
nature of CAPs conferred by the presence of both hydropho-
bic amino acid residues (Trp, Phe, Leu) and basic amino acid
residues (Lys, Arg, His) leading to a net positive charge of
CAPs.7 The role of positively charged amino acids in CAPs is
especially noteworthy, since they form the anchors for inter-
actions with the negatively charged phospholipids. Bacterial
membranes are net negatively charged because of the pres-
ence of anionic phospholipids such as phosphatidylglycerol
and phosphatidylserine in Gram-negative bacteria,2 or
teichoic and lipoteichoic acids in Gram-positive bacteria.8 In
contrast, eukaryotic cell membranes are composed of more
neutral zwitterionic lipids like phosphatidyl choline and cho-
lesterol. In these cells, the anionic lipids are located in the
inner part of the plasma membrane.
The cytotoxic effect on both prokaryotic and eukaryotic
cells is closely related to the structure of the CAPs and the na-
ture of their interaction with the membranes. The presence
in CAPs of amino acid residues like tryptophan tends to lead
to stronger interactions with membranes causing lysis,
whereas leucine tends to increase the lipophilicity of CAPs fa-
cilitating crossing membranes.9 Also, the replacement of very
hydrophobic residues in the apolar face of CAPs, by less hy-
drophobic amino acid residues reduces interaction with red
blood cell membranes leading to diminished haemolysis.10
This duality in the behaviour of the CAPs is fascinating
and poses a great challenge for tuning their activity. In many
cationic antimicrobial peptides, this can be achieved by alter-
ing the balance between the charged and hydrophobic resi-
dues.11 Therefore, in this research, we wished to look at the
charge character of the positively charged amino acids by
changing the naturally occurring positively charged nitrogen
amino acids to positively charged phosphorus containing
amino acids. To our knowledge, the influence on the bio-
activity of CAPs containing other positively charged atoms
has not been studied so far. By introducing phosphonium
amino acids, we can study the triangular relation between
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antimicrobial activity (AM), cell penetrating ability (CP) and
cellular toxicity (CT) of a new class of CAPs. Determination of
the relative AM, CP and CT parameters, should steer us ulti-
mately towards cationic amphiphilic peptides with optimal
activity and selectivity. It might be even possible that, by judi-
cious modification of the sequences, we will be able to tune
the AM, CP and CT properties.
As a suitable starting point for our studies we chose
HHC10, a well-known antimicrobial peptide developed in the
group of Hancock,12 (Fig. 1) which is an optimized AMP with
low cytotoxicity properties as was evidenced from its low
haemolysis properties. HHC10 has potent broad-spectrum
antimicrobial activity against multidrug resistant superbugs
in vitro but the presence of Lys and Arg residues, makes
HHC10 also susceptible to proteolytic digestion by trypsin-
like proteases.13 An attractive possibility to reduce this pro-
teolytic degradation is the incorporation of D-amino acids.
For example, we have recently shown that synthesis of the
D-isomer of the HHC10 peptide led to an increase of its sta-
bility in serum and subsequent incorporation into a coat-
ing14,15 led to a serum-stable antimicrobial coating. Thus, in-
troduction of other unnatural amino acids such as analogues
of the positively charged lysine and arginine residues with a
different positively charged atom, that is not recognised by
proteolytic enzymes, may favourably affect the bioactivity or
stability.
In this work we describe the development of these new
positively charged amino acids, containing a phosphonium
moiety, used in the synthesis of new CAPs with possible me-
dicinal chemistry applications. The antimicrobial and cyto-
toxic activities of these phosphonium-HHC10 analogues were
studied, which led to the development of fluorescent versions
to investigate their behaviour in mammalian cells and study
of potential cell penetrating properties.
Results and discussion
Cysteine is perhaps the most versatile amino acid for post-
synthesis modification by alkylation either in a peptide or a
protein due to the excellent nucleophilic character of the
thiol group.16 Work developed by Shokat et al., describes the
functionalisation of cysteine to produce a series of methyl-
ated lysine analogues.17 By using suitable alkylating reagents
containing a phosphonium group, it was possible to
synthesise the phosphonium isosteric amino acid of (tri-
methylamine)lysine 6 (‘KP’) and one as a more distant ana-
logue of the positive charge present in the side chain of argi-
nine 7 (‘RP’).
The required bromo phosphonium alkylating reagents 4
and 5 were prepared by addition of trimethyl phosphine to
1,2-dibromo ethane and 1,3-dibromo propane, respectively.
Using 4, it was possible to prepare the pure phosphonium
cysteine derivative 6 directly from Fmoc–Cys–OH 2. However,
to facilitate purification of phosphonium derivative 7, synthe-
sis was more conveniently carried out starting from Fmoc–
Cys–OMe 3, followed by ester hydrolysis under the acidic con-
ditions of the work up (Scheme 1).
In principle, it is possible to introduce the desired phos-
phonium cysteine derivatives post-assembly of the peptides
in which the positively charged chains must be incorporated.
This can be achieved by alkylation of deprotected cysteine de-
rivatives using alkylating agents 4 or 5. However, it was found
that completion of the alkylation reactions was difficult to re-
alize in peptides containing more than one cysteine residue.
In addition, peptides (for example CAP 9) containing two dif-
ferent phosphonium cysteine derivatives cannot be synthe-
sized post-assembly. Hence, it was decided to employ the
modified amino acid building block approach and use Fmoc
protected derivatives 6 and 7 in a manual solid phase synthe-
sis approach on Rink amide resin.18 To synthesise the three
different HHC10 phosphonium analogues 8–10 (Fig. 2), DIC/
Scheme 1 Synthesis of the phosphonium containing amino acid derivatives.
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Oxyma-pure was used as a coupling reagent after failed
attempts of using HCTU/DIPEA. After cleavage and depro-
tection, crude peptides were purified by reverse phase HPLC
and obtained with purities >97%.
For the evaluation of the bio-activity of phosphonium
CAPs 8–10 their antimicrobial properties, (eukaryotic) cellular
toxicity and haemolytic activity were determined (Table 1).
Determination of the antimicrobial activity using the mod-
ified MIC method for cationic amphiphilic peptides devel-
oped by Hancock and co-workers19 showed that peptides
CAPs 8–10 were virtually inactive towards E. coli compared to
HHC10. This inactivity towards bacteria was paralleled by a
lower cellular toxicity towards HEK 293 cells as compared to
HHC10 using the Alamar blue assay.20 The haemolytic activ-
ity of CAPs 8–10 was also considerably lower than that of
HHC10, which is known to possess relatively low haemolytic
properties.
The considerable antimicrobial activity of HHC10 is
probably related to the high interaction properties of Arg/
Trp rich peptides with bacterial membranes.22 Similarly,
HHC10 can interact with membranes of mammalian cells,
which led to a decrease of cell viability and increase of the
haemolytic activity. However, the increased size of the phos-
phorus atom as well as the presence of methyl groups likely
led to a more diffuse positive charge of the side chains of
the phosphonium CAPs and therefore less strong interaction
with the negatively charged bacterial membrane, thereby de-
creasing the antimicrobial effect. Concomitantly, this de-
crease of the positive charge character might be responsible
for the diminished eukaryotic toxicity and haemolysis of
CAPs 8–10.
This relatively low toxicity of CAPs 8–10 prompted us to in-
vestigate two additional phosphonium containing peptides
that might have better antimicrobial properties. To achieve
this, Trp amino acid residues were changed to Phe-residues
in the repetitive sequence XPFFXPFFXPFFXP (‘XP’ represents
an incorporated phosphonium amino acid) leading to 11 and
12, which were synthesized by solid phase peptide synthesis
(Fig. 3). This sequence is based on the cationic bactericidal
peptide KFFKFFKFFK previously used by our group23 which
was reported to have a direct activity against E. coli24 and low
eukaryotic toxicity and haemolysis.
Interestingly, the antimicrobial activity of 11 and 12 in-
creased slightly (MIC 32 and 64 μM, respectively), but was
still considerably less than that of HHC10 (1.5 μM).
According to Eriksson et al.,25 the KFFKFFKFFK sequence
acts as a cell-permeabilising peptide for the delivery of pep-
tide nucleic acids, thus hinting at possible favourable cell
penetrating properties of 11 and 12.
To investigate the potential cell penetrating properties in-
duced by the phosphonium containing amino acid residues,
Table 1 Antimicrobial and cytotoxicity evaluation of the phosphonium
based HHC10 analogues and comparison with HHC10: lower antimicro-
bial activities of the phosphonium peptides are translated into a dimin-
ished toxicity profile as compared to HHC10. All experiments were carried
out in triplicate and cell viability and haemolytic effect are presented as






at 256 μM (%)
Haemolysis of
horse erythrocytes
at 512 μM (%)
8 64 85 ± 6 3.4 ± 0.1
9 64 87 ± 4 3.3 ± 0.1
10 128 103 ± 3 3.2 ± 0.1
HHC10 1.5 (ref. 21) 2.0 ± 1.5 14.3 ± 3.6 Fig. 3 Phosphonium analogues of the bactericidal peptide KFFKFFKFFK.
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a small collection of peptides in which the Phe-residues in
the XPFFXPFFXPFFXP sequence of peptides 11 and 12 were
changed by other common hydrophobic residues (Trp, Leu,
Ile), was synthesised thereby affording six additional
phosphonium-CAPs (13–18) (Fig. 5). The cytotoxicity of these
compounds was tested and compared to compounds 11 and
12 trying to understand the relation of the hydrophobic resi-
dues on the activity of the phosphonium-CAPs (Table 2).
Replacement of the phenylalanine residues by tryptophan
residues in the peptide increased the cytotoxicity of the
phosphonium-CAPs as was evidenced by compound 13 which
led to a very low cell viability and the highest haemolytic ef-
fect of all synthesised peptides. In addition, interaction of
Trp rich sequences with membrane components and disrup-
tion of red blood cells was increased as comparison of the
haemolytic effect of compounds with similar cell viability like
compounds 11 and 14 showed. The latter had a higher
haemolytic activity. Peptides 15–18 showed a lower toxicity
on red blood cells.
Nevertheless, the generally low toxicity of these phospho-
nium CAPs is remarkable. We think that this is due to the
character of these added positively charged amino acids as
compared to the positively charged amino acid residues (Arg,
Lys, His), which are normally found in antimicrobial peptides
and cytotoxic peptides. The phosphonium charge is much
more diffuse and therefore interaction with the negative
charges of the lipids are weaker, possibly sufficient for cell
penetrating properties but less strong for a display of toxicity
effects or antimicrobial activity.
To evaluate possible cell penetrating properties of phos-
phonium CAPs, fluorescent derivatives of the phospho-
nium HHC10 analogues (8–10) and XPFFXPFFXPFFXP pep-
tide sequences (11, 12) were prepared. These peptides
were selected because of their similarly low antimicrobial
and low cytotoxic activities, thereby rendering them poten-
tially interesting to serve as cell penetrating peptide carriers
for future cargos.
For visualization by fluorescence microscopy the BODIPY-
Fl label, which was prepared according to a modified litera-
ture procedure,26 was coupled to the N terminus of the pep-
tide mimics using EDCI·HCl and 6-Cl HOBt in DMF leading
to fluorescent BODIPY-CAPs 19–23 (Fig. 4).
MCF7 cells were incubated with solutions (20 μM) of the
fluorescent peptides according to a slightly modified litera-
ture protocol (Fig. 5).27 These cells were used because of their
well-known morphology and controlled grow rate. The cells
were observed with an Axiovert fluorescent microscope. Con-
trols using the fluorescent BODIPY ligand were carried out to
confirm that the green fluorescence was due to the presences
of the fluorescent peptides (see ESI†).
The observed association of the fluorescent CAPs with
membranes was not merely due to the CAPs associating with
just any lipid containing organelle, since neither Golgi, ER
nor mitochondria were stained. The staining was diffuse
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throughout the cells but stayed in place. There was no real
entry into the nucleus. In general, and perhaps not entirely
unexpectedly, association of all fluorescent phosphonium
CAPs seemed to be similar. Subtle differences in the staining
may indicate the importance of structural variations of phos-
phonium CAPs. For example, tryptophan/KP containing CAP
19 seemed to be uniformly distributed over membrane
containing structures, whereas tryptophan/RP/KP containing
CAP 20 showed staining of well localised areas in cell periph-
ery with diffuse staining in the cytoplasm but not the
nucleus. The bright actin patches were reflected in bright
patches of the CAP. Tryptophan/RP containing CAP 21
showed a more diffuse staining throughout the cytoplasm as
no dark nuclear area was visible looking at the green fluores-
cence of CAP 21. Here also the bright actin patches were
reflected in bright patches of the CAP. Phenylalanine/KP
containing CAP 22 showed a granular pattern and peri-
nuclear staining with possible association with areas inside
or around (Golgi-area) the nucleus. Finally, phenylalanine/RP
containing CAP 23 showed a less granular pattern than 22
with diffuse association with areas inside the nucleus. There
was a very clear perinuclear staining and here too the
actin bright patches were also bright in the bright patches of
this CAP.
Table 2 Cytotoxicity evaluation of the phosphonium-CAPs: ‘KP’ represents the phosphonium isostere of (trimethyl)lysine and ‘RP’ with a phosphonium
side chain length comparable to that of arginine. All peptides are TFA salts with C-terminal amide and free N-terminus. All experiments were carried out
in triplicate and cell viability and haemolytic effect are presented as the mean ± SEM
CAP Sequence
Cell viability of HEK 293
cells at 512 μM (%)
Haemolysis of horse
erythrocytes at 512 μM (%)
11 H-KPFFKPFFKPFFK−NH2 46 ± 1 1.5 ± 0.1
12 H-RPFFRPFFRPFFRP−NH2 83 ± 1 3.1 ± 0.1
13 H-KPWWKPWWKPWWKP−NH2 14 ± 5 11.0 ± 1.6
14 H-RPWWRPWWRPWWRP−NH2 44 ± 1 5.8 ± 1.0
15 H-KPLLKPLLKPLLKP−NH2 110 ± 21 2.1 ± 0.5
16 H-RPLLRPLLRPLLRP−NH2 93 ± 3 0.6 ± 0.2
17 H-KPIIKPIIKPIIKP−NH2 120 ± 23 2.3 ± 1.5
18 H-RPIIRPIIRPIIRP−NH2 83 ± 29 3.9 ± 0.7
HHC10 H-KRWWKWIRW−NH2 0.0 14.3 ± 3.6
Fig. 5 Fluorescence micrographs of MCF7 cells with 20 μM of BODIPY-CAPs 19, 20, 21, 22 and 23. Blue fluorescence of DAPI (4′,6-
diamidinophenylindole) stained nuclei and red fluorescent components of the cytoskeleton were obtained by marking with Rhodamine phalloidin.
Green (BODIPY) fluorescent cationic amphiphilic peptides showed their cellular uptake and localisation. Pictures were merged to visualise the
localisation of the fluorescent peptides inside the cell thus confirming their cell penetrating properties. The white scale bar in the right figure of
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Conclusions
A new class of positively charged non-natural amino acids de-
rived from cysteine was synthesised. These were used to pre-
pare a new category of cationic amphiphilic peptides that are
less toxic than normal lysine or arginine based CAPs, possibly
due to presence of a more diffused charge of the positive
phosphonium moiety. Their antimicrobial activity is lower
than the well-known AMP HHC10. However, their low toxicity
and ability to cross membranes without causing damage was
further investigated to evaluate possible cell penetrating prop-
erties. This study showed that introduction of phosphonium
amino acids diminished the toxicity compared to of positively
charged nitrogen containing peptides such as HHC10. Further
modification of the sequence of the peptides by introduction
of other lipophilic amino acid residues favoured their cell pen-
etrating properties. The data showed that this class of phos-
phonium based CAPs may well comprise a new category of cell
penetrating peptides with low cytotoxicity.
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